Head-to-head · WeighScore
TelePeptide vs Zeuss
The verdict
Zeuss takes it — 69.2/100 to 62.3/100.
Zeuss grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Zeuss is a multi-vertical telehealth platform offering compounded semaglutide and tirzepatide for weight loss alongside TRT, HRT, skin, and hair services.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | TelePeptide | Zeuss |
|---|---|---|
| WeighScore | 62.3/100 | 69.2/100 |
| Grade | C | C |
| Scorecard rank | #273 | #132 |
| Semaglutide | $199/mo (starting dose, annual plan, compounded oral) | $125/mo (compounded) |
| Tirzepatide | $219/mo (starting dose, annual plan, compounded oral) | $175/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #273 · C
Strengths
- LegitScript-certified (seal ID 49966407); 503A-licensed compounding pharmacies
- All-inclusive from $169/mo annual — physician eval + Rx + medication + shipping, no hidden fees
- Broadest formulation menu: injectable sema/tirz, oral dissolvable tablets, sema+naltrexone, microdose combos
- 24/7 care team messaging + regular check-ins + dosage adjustments included at every tier
- 48 states + DC coverage (excludes only AK + MS); no insurance required; cancel anytime
Where it loses points
- Compounded medications are not FDA-approved; no pharmacy partner named publicly
- Monthly billing costs more — $199/mo (monthly) vs $169/mo (annual) for semaglutide injectable; best rate requires annual prepay
- Labs not included in any plan
- Founder disclosed by first name only (Ahmed); no physician names or clinical leadership disclosed publicly
- Tirzepatide injectable at $249/mo (monthly billing) is above the compounded market average
Graded #132 · C
Strengths
- One-time-purchase model with no subscription — genuinely rare among DTC GLP-1 providers
- Publishes the FDA compounded-medication disclaimer
- Names both 503A and 503B compounding pathways — uncommon transparency
- Bundled pricing covers provider review, meds, and cold-chain shipping with no hidden fees
- Full refund if a physician can't prescribe
Where it loses points
- 503A pharmacy partner not named (only generic '503A and 503B state-licensed' framing)
- LegitScript certification not mentioned
- No named medical director or physician leadership
- Full states-served list not disclosed
- Corporate legal entity not disclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.